Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Optic Atrophy | 3 | 2023 | 16 | 1.220 |
Why?
|
| Optic Neuropathy, Ischemic | 3 | 2023 | 8 | 0.610 |
Why?
|
| Infarction, Posterior Cerebral Artery | 2 | 2023 | 2 | 0.430 |
Why?
|
| Thymoma | 2 | 2023 | 12 | 0.430 |
Why?
|
| Thymus Neoplasms | 2 | 2023 | 17 | 0.420 |
Why?
|
| Optic Neuritis | 2 | 2023 | 21 | 0.420 |
Why?
|
| Retinal Artery Occlusion | 2 | 2023 | 13 | 0.410 |
Why?
|
| Retinal Vein Occlusion | 2 | 2023 | 14 | 0.410 |
Why?
|
| Optic Nerve Diseases | 2 | 2022 | 22 | 0.400 |
Why?
|
| Papilledema | 2 | 2022 | 27 | 0.400 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2023 | 1548 | 0.310 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 2 | 2023 | 8 | 0.260 |
Why?
|
| Humans | 27 | 2023 | 50503 | 0.260 |
Why?
|
| Hemangioma, Cavernous | 1 | 2023 | 6 | 0.220 |
Why?
|
| Tuberculosis, Meningeal | 1 | 2023 | 4 | 0.220 |
Why?
|
| Subclavian Steal Syndrome | 1 | 2023 | 5 | 0.210 |
Why?
|
| Neuromyelitis Optica | 1 | 2023 | 7 | 0.210 |
Why?
|
| Exotropia | 1 | 2023 | 9 | 0.210 |
Why?
|
| Strabismus | 1 | 2023 | 14 | 0.210 |
Why?
|
| Ocular Motility Disorders | 1 | 2023 | 17 | 0.210 |
Why?
|
| Subclavian Artery | 1 | 2023 | 19 | 0.210 |
Why?
|
| Myasthenia Gravis | 1 | 2023 | 17 | 0.210 |
Why?
|
| Delayed Diagnosis | 1 | 2023 | 24 | 0.210 |
Why?
|
| Pituitary Apoplexy | 1 | 2022 | 4 | 0.210 |
Why?
|
| Scotoma | 1 | 2022 | 7 | 0.210 |
Why?
|
| Skull | 1 | 2023 | 75 | 0.210 |
Why?
|
| Sphenoid Sinusitis | 1 | 2022 | 2 | 0.210 |
Why?
|
| Wernicke Encephalopathy | 1 | 2022 | 7 | 0.210 |
Why?
|
| Cerebellar Ataxia | 1 | 2022 | 5 | 0.210 |
Why?
|
| Apraxias | 1 | 2022 | 9 | 0.210 |
Why?
|
| Tonic Pupil | 1 | 2022 | 2 | 0.210 |
Why?
|
| Mydriasis | 1 | 2022 | 3 | 0.200 |
Why?
|
| Eyelid Diseases | 1 | 2022 | 12 | 0.200 |
Why?
|
| Spine | 1 | 2023 | 90 | 0.200 |
Why?
|
| Ependymoma | 1 | 2022 | 7 | 0.200 |
Why?
|
| Carotid-Cavernous Sinus Fistula | 1 | 2022 | 12 | 0.200 |
Why?
|
| Glycogen Storage Disease Type V | 1 | 2022 | 4 | 0.200 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2022 | 14 | 0.200 |
Why?
|
| Takayasu Arteritis | 1 | 2022 | 2 | 0.200 |
Why?
|
| Reflex, Pupillary | 1 | 2022 | 7 | 0.200 |
Why?
|
| Rhabdomyolysis | 1 | 2022 | 12 | 0.200 |
Why?
|
| Diabetic Retinopathy | 1 | 2022 | 44 | 0.200 |
Why?
|
| Retinal Artery | 1 | 2022 | 5 | 0.200 |
Why?
|
| Intracranial Hypertension | 1 | 2022 | 31 | 0.200 |
Why?
|
| Pupil | 1 | 2022 | 29 | 0.200 |
Why?
|
| Giant Cell Arteritis | 1 | 2022 | 12 | 0.200 |
Why?
|
| Multiple Sclerosis | 1 | 2022 | 65 | 0.200 |
Why?
|
| Pseudotumor Cerebri | 1 | 2022 | 26 | 0.190 |
Why?
|
| Visual Acuity | 1 | 2023 | 144 | 0.190 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2022 | 106 | 0.190 |
Why?
|
| Ophthalmology | 1 | 2022 | 32 | 0.190 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2022 | 76 | 0.190 |
Why?
|
| Vascular Malformations | 1 | 2023 | 102 | 0.180 |
Why?
|
| Embolization, Therapeutic | 1 | 2022 | 88 | 0.180 |
Why?
|
| Vaccines | 1 | 2022 | 50 | 0.180 |
Why?
|
| Glioblastoma | 1 | 2022 | 94 | 0.180 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 279 | 0.160 |
Why?
|
| Brain Neoplasms | 1 | 2022 | 291 | 0.150 |
Why?
|
| Optic Nerve | 2 | 2022 | 50 | 0.100 |
Why?
|
| Vision Disorders | 2 | 2023 | 59 | 0.100 |
Why?
|
| Dilatation | 2 | 2022 | 26 | 0.100 |
Why?
|
| Risk Factors | 2 | 2022 | 3724 | 0.050 |
Why?
|
| Prothrombin | 1 | 2023 | 4 | 0.050 |
Why?
|
| Cerebral Revascularization | 1 | 2023 | 10 | 0.050 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2023 | 19 | 0.050 |
Why?
|
| Orbit | 1 | 2023 | 27 | 0.050 |
Why?
|
| Vitreous Hemorrhage | 1 | 2022 | 4 | 0.050 |
Why?
|
| Hemianopsia | 1 | 2022 | 5 | 0.050 |
Why?
|
| Vitreous Body | 1 | 2022 | 20 | 0.050 |
Why?
|
| Carotid Arteries | 1 | 2023 | 84 | 0.050 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2022 | 31 | 0.050 |
Why?
|
| Visual Fields | 1 | 2022 | 39 | 0.050 |
Why?
|
| Carotid Stenosis | 1 | 2023 | 63 | 0.050 |
Why?
|
| Thalamus | 1 | 2022 | 38 | 0.050 |
Why?
|
| Optic Chiasm | 1 | 2022 | 9 | 0.050 |
Why?
|
| Rare Diseases | 1 | 2022 | 43 | 0.050 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2022 | 6 | 0.050 |
Why?
|
| Blindness | 1 | 2022 | 31 | 0.050 |
Why?
|
| Acetazolamide | 1 | 2022 | 19 | 0.050 |
Why?
|
| Ciliary Arteries | 1 | 2022 | 3 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2022 | 117 | 0.050 |
Why?
|
| Genotype | 1 | 2023 | 533 | 0.050 |
Why?
|
| Vitrectomy | 1 | 2022 | 59 | 0.050 |
Why?
|
| Fluorescein Angiography | 1 | 2022 | 34 | 0.050 |
Why?
|
| Syndrome | 1 | 2022 | 240 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2023 | 1033 | 0.040 |
Why?
|
| Mutation | 1 | 2023 | 1280 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2023 | 1033 | 0.030 |
Why?
|
| Aged | 1 | 2022 | 9741 | 0.020 |
Why?
|